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LETTER TO THE EDITOR
Tracheoesophageal
Fistula Associated with
Bevacizumab 21
Months after
Completion of
Radiation Therapy
To the Editor:
We present a case of a 48-year-old
man with stage IIIa non-small cell lung
cancer treated with preoperative concur-
rent chemotherapy and radiation therapy
(RT). Two years later, he was treated
with salvage bevacizumab and chemo-
therapy and developed a fatal tracheo-
esophageal fistula (TEF).
The patient had a RUL mass and
mediastinoscopy-proven right paratra-
cheal lymphadenopathy. He was treated
with definitive RT (66 Gy) and weekly
carboplatin and paclitaxel. Maximum
esophageal dose was 68.1 Gy. Absolute
volume receiving 68 Gy was 0.03 (Fig-
ure 1). Eight weeks later, he had a right
upper lobectomy with lymph node dis-
section, pT1N0M0. Residual mass was
necrotic with rare tumor cells.
Seventeen months after diagnosis,
he had biopsy-proven chest wall recur-
rence. Computed tomography showed
progressive RUL collapse, although no
mediastinal mass. He was treated with
carboplatin, gemcitabine, and bevaci-
zumab. Fourteen days after cycle 1, he
was diagnosed with RLL pneumonia.
Twenty-three days later, he had progres-
sive dysphagia and cough. Swallow
study showed a TEF. Chest computed
tomography confirmed erosion of the
posterior wall of the distal trachea, me-
diastinal air, oral contrast within the
pleural space, and a tracheoesophageal
mass (Figure 2). Mediastinal recurrence
was suspected, although not histologi-
cally confirmed. An esophageal stent
was placed with symptomatic relief.
One month later, bronchoscopy and
esophagogastroduodenoscopy showed
complete erosion of the esophagus and
posterior tracheal wall from the cricoid
cartilage to carina. Biopsies were nega-
tive. The patient died of pneumonia sev-
eral days later.
Acute esophageal toxicity is a
common side effect of RT and predicts
for late toxicity.1Esophageal dose in this
case was acceptable by published pa-
rameters. The patient had minimal acute
esophageal toxicity. Severe late compli-
cations were not anticipated.
Bevacizumab is associated with
gastrointestinal complications, including
TEF.2–5 A drug warning was issued in
April 2007 after formation of three TEF
in 29 patients treated on a phase II study
with concurrent thoracic RT, chemother-
apy, and bevacizumab.4 TEF occurred
during maintenance bevacizumab. Six
other cases of TEF with concurrent RT
and bevacizumab for lung and esophageal
cancer have been reported. TEF formation
has also been reported in head and neck
cancer with bevacizumab and concurrent
chemoradiotherapy.2
Although delayed gastrointestinal
complications associated with bevacizumab
after RT are described for colorectal cancer,
delayed TEF in patients with lung cancer
have not been widely reported.
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FIGURE 1. Isodose lines showing radiation dose distribution covering the right
paratracheal lymph node (red) and the esophagus (blue).
FIGURE 2. Computed tomography (CT) image with erosion of distal trachea (red
arrow) and oral contrast in the connecting cavity (yellow arrow). Tracheoesophageal
fistula (TEF) was suspected and confirmed with esophagogastroduodenoscopy.
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Goodgame et al5 have reported a
case of TEF in a patient treated with
salvage chemotherapy and bevacizumab
2 months after chemoradiotherapy. Bi-
opsy of the fistulous tract was negative,
although imaging showed progressive
disease in the mediastinum and liver.
TEFs are a rare complication of
RT for lung cancer. This case and the
case previously presented5 suggest an
association between TEF formation and
salvage bevacizumab after high-dose
RT. In both cases, regional progressive
disease may have been a contributing
factor to TEF formation. The combina-
tion of increasing aggressiveness of
therapy for non-small cell lung cancer
and prolonged survival is likely to un-
cover unanticipated late complications.
Use of this class of drugs for recurrent
lung cancer needs to be approached with
caution, particularly in patients treated
previously with high-dose RT.
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